Immuno-Oncology Cell Therapy Market Size and Future Outlook with Clinical Pipeline Insights and Key Indications Driving Industry Expansion

InsightAce Analytic Pvt. Ltd. announces the release of the market assessment report on "Global Immuno-Oncology Cell Therapy Market Therapy Type (CAR-T Cells, NK & NKT Cells, TAA/TSA targeted T Cell, TCR T Cell, Cytokine-induced killer cells, Dendritic cells, Macrophages, and Other Cell Therapies), Major Indication (Head & Neck Cancer, Lung Cancer, Kidney Cancer, Melanoma, Lymphoma, Leukemia, and Others) - Technology Trends, Clinical Trial/Pipeline Analysis, Revenue and Forecast Till 2034."

According to the latest market research research, the global Immuno-oncology cell therapies market size is valued at USD 11.9 Billion in 2024, and it is expected to reach USD 95.3 Billion by the year 2034 recording a promising CAGR of 23.2% from 2025 through 2034.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/1083

The advent of novel immunotherapies has profoundly reshaped the oncology sector. Immunotherapy, a relatively recent advancement in cancer treatment, leverages the body's immune system to identify, target, and eliminate malignant cells. Immuno-oncology represents a biological approach designed to enhance the immune response to inhibit cancer progression. Emerging next-generation therapies are poised to rapidly transform the oncology market during the forecast period, supported by ongoing clinical trials and recent regulatory approvals that underscore their potential as either first-line or subsequent treatment options.

Among the most notable breakthroughs since chemotherapy is the approval of CAR-T cell therapies. Current clinical development efforts are concentrated on expanding indications for T-cell therapies, improving the safety profiles of these treatments, and optimizing manufacturing processes for greater efficiency. Moreover, the COVID-19 pandemic has amplified the demand for immuno-oncology cell therapies, further driving market growth.

The expansion of the immuno-oncology cell therapy market is driven by several factors, including the swift adoption of immunotherapies over conventional cancer treatments, advances in bioinformatics, the high global incidence of cancer, and the growing emphasis on personalized medicine. According to the American Cancer Society, the United States alone was projected to witness approximately 1.8 million new cancer cases and over 600,000 cancer-related deaths in 2020. Increased research initiatives and funding from governmental health bodies and major pharmaceutical companies have further accelerated innovation in immuno-oncology therapies. Additionally, the integration of bioinformatics tools has reduced drug development costs and timelines, enabling pharmaceutical firms to more effectively monitor and evaluate therapeutic candidates. This technological advancement fosters greater research interest and facilitates the development and adoption of novel cancer immunotherapies, thereby propelling market growth.

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-04

Nonetheless, the immuno-oncology cell therapy market growth is anticipated to be constrained by factors such as the high cost of therapies, stringent regulatory requirements related to biomarker validation, and inadequate reimbursement policies throughout the forecast period. From a geographic perspective, North America is expected to maintain market leadership due to substantial healthcare expenditures and high levels of public awareness. The European region also holds a significant share of the market, driven by robust governmental support for research and development, as well as increased clinical trial activity within the healthcare sector.

The Asia Pacific region is projected to experience the fastest growth between 2021 and 2030, attributed to the rising prevalence of cancer, greater adoption of bioinformatics tools for drug design, and enhanced government investment in healthcare infrastructure. Key markets in this region include China, India, and Japan.

The immuno-oncology cell therapy market remains highly fragmented, characterized by numerous players with therapeutic candidates currently in clinical development, many of which are expected to receive approval in the near future. Leading companies are actively pursuing strategies such as product launches in established markets, strategic partnerships, geographic expansion, licensing agreements, mergers, and acquisitions to strengthen their market positions. For example, in January 2021, Novartis (Switzerland) entered into a collaboration agreement with BeiGene, Ltd. to in-license tislelizumab for major markets outside China. This partnership is anticipated to enhance Novartis's presence in the rapidly expanding checkpoint inhibitor segment. Tislelizumab is an anti-PD-1 monoclonal antibody specifically engineered to reduce binding affinity to Fcγ receptors on macrophages, thereby potentially improving therapeutic efficacy.

The global immuno-oncology cell therapy market covers prominent players like Agios Pharmaceutical, Atara Biotherapeutics, Novartis, Juno Therapeutics, Allogene Therapeutics, Shenzhen BinDeBio Ltd., Kite Pharma, Autolus Limited, China Immunotech Co., Ltd., Bellicum Pharmaceuticals, bluebird bio, CARsgen Therapeutics, Cell Design Labs, Calibr, Carina Biotech, Editas Medicine, Celgene Corporation, Cellectis, Cell Medica, Amgen, Celularity, Celyad, Fortress Bio, Fate Therapeutics, Gilead Sciences, JW Therapeutics, Mustang Bio, Ziopharm, Sorrento Therapeutics, Inc., Medigene, Medisix Therapeutics, Precision Biosciences, Lion TCR, Nanjing Legend Biotech, Posedia Therapeutics, Zelluna Immunotherapy, and others prominent players.

Key Developments:
• In Dec 2021, Novartis unveiled T-ChargeTM, its next-generation CAR-T platform, which will serve as the platform for several new investigational CAR-T cell therapies in the Novartis pipeline. Novartis continues to improve the T-Charge platform, which protects T cell stemness, a crucial attribute linked to therapeutic potential, while also implementing significant process savings.
• In Nov 2021, CARsgen Therapeutics Holdings Limited announced that CT041, an autologous CAR T-cell product candidate against the claudin18.2 protein (CLDN18.2) for the treatment of gastric/gastroesophageal junction cancer (GC/GEJ), has been granted Priority Medicines (PRIME) eligibility by the European Medicines Agency (EMA).
• In Aug 2021, The U.S. Food and Drug Administration (FDA) has approved Kite's Investigational New Drug (IND) application for KITE-363, the company's first chimeric antigen receptor (CAR) T-cell treatment that targets two antigens, CD19 and CD20. Kite intends to begin a multi-center Phase 1 clinical trial assessing KITE-363 in large B-cell lymphoma with this approval (LBCL).
• In Aug 2019, Celgene and Immatics Biotechnologies will collaborate to explore breakthrough adoptive cell therapies for a variety of diseases. Immatics plans to develop T-Cell Receptor Engineered T-cell Therapy (TCR-T) programmes targeting solid tumour targets found by Immatics' XPRESIDENT technology under the terms of the firms' strategic collaboration and option agreement.
• In Jan 2018, Celgene Corporation (U.S.) acquired Juno Therapeutics, Inc. (U.S.), a company engaged in the development of CAR T and TCR (T cell receptor) therapeutics. This acquisition added a novel scientific platform and scalable manufacturing capabilities to complement Celgene's haematology and oncology leadership.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/1083

Market Segments
Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2030 based on Therapy Type
• CAR-T Cells
• N.K. & NKT Cells
• TAA/TSA targeted T Cell
• TCR T Cell
• Cytokine-induced killer cells
• Dendritic cells
• Macrophages
• Other Cell Therapies
Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2030 based on Major Indication
• Head & Neck Cancer
• Lung Cancer
• Kidney Cancer
• Melanoma
• Lymphoma
• Leukemia
• Others
Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2030 based on Region
• Europe
• North America
• Asia Pacific
• Latin America
• Middle East & Africa
Europe Immuno-oncology cell therapies market Revenue (US$ Million) by Country, 2022 to 2030
• Germany
• France
• Italy
• Spain
• Russia
• Rest of Europe
North America Immuno-oncology cell therapies market Revenue (US$ Million) by Country, 2022 to 2030
• U.S.
• Canada
Asia Pacific Immuno-oncology cell therapies market Revenue (US$ Million) by Country, 2022 to 2030
• India
• China
• Japan
• South Korea
• Australia & New Zealand
Latin America Immuno-oncology cell therapies market Revenue (US$ Million) by Country, 2022 to 2030
• Brazil
• Mexico
• Rest of Latin America
Middle East & Africa Immuno-oncology cell therapies market Revenue (US$ Million) by Country, 2022 to 2030
• South Africa
• GCC Countries
• Rest of Middle East & Africa

Why should buy this report:
• To receive a detailed analysis of the prospects for global Immuno-oncology cell therapies market
• To receive clinical trial/pipeline analysis of Immuno-oncology cell therapies market
• To analyze the Immuno-oncology cell therapies market drivers and challenges
• To get information on Immuno-oncology cell therapies market size value (US$ Mn) forecast till 2030
• Mergers & Acquisition, Major Investments, in Immuno-oncology cell therapies market industry

Read Overview Report- https://www.insightaceanalytic.com/report/global-immuno-oncology-cell-therapy-market/1083

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 551 226 6109
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.